Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorImmunocore Ltd
About this trial
This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.
Eligibility criteria
Qualifiers
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
HLA-A*02:01-positive
Histologically confirmed advanced colorectal, esophageal, gastric, or ovarian carcinoma
Archived or fresh tumor tissue sample that must be confirmed as adequate
Disqualifiers
Symptomatic or untreated central nervous system metastasis
Recent bowel obstruction
Ongoing ascites or effusion requiring recent drainages
Significant ongoing toxicity from prior anticancer treatment
Trial design
Treatments tested in this trial
- IMC-R117C
- Chemotherapy drug
- Chemotherapy drug
- Kinase inhibitor
- Antiangiogenic Agent
- Monoclonal antibody
Treatment groups
600 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov